1. Red Sea Ecosystem
====================

Marine ecosystems cover nearly 70% of the earth's surface, averaging almost 4 km in depth and are proposed to contain over 80% of the world's plant and animal species \[[@B1-marinedrugs-13-03154]\]. Exact marine biodiversity is less certain since between one-third and two-thirds of marine organisms have yet to be described \[[@B2-marinedrugs-13-03154]\]. Worldwide there are approximately 226,000 marine eukaryotes currently reported, while close to a million total species are estimated, based on calculations by marine biologists using statistical predictions \[[@B2-marinedrugs-13-03154]\]. Considering that constituents from higher plants along with metabolites from terrestrial microorganisms have provided a substantial fraction of the natural-product-derived drugs currently used in Western medicine \[[@B3-marinedrugs-13-03154]\], the potential to vastly expand the number and diversity of natural products by mining marine eukaryotes as well as associated prokaryotes from the richly diverse Red Sea ecosystem seems attainable. In fact, just within the past quarter century, the search for new marine metabolites has resulted in the isolation of upward of 10,000 compounds \[[@B4-marinedrugs-13-03154]\], many of which exhibit biological activity. Despite the fact that marine biodiversity far exceeds that of terrestrial ecosystems, research of marine natural products as pharmaceutical agents, is still in its infancy. Factors that contribute to the gap between terrestrial and marine derived natural products include a paucity of ethno-medical history from marine sources as well as impediments associated with collecting, identifying and chemical analysis of marine materials \[[@B5-marinedrugs-13-03154]\].

Notwithstanding, a combination of new diving techniques and implementation of remotely operated pods over the last decade has facilitated the characterization of marine-derived metabolites. This review encompasses secondary metabolites derived from marine invertebrates, a largely diverse group of fixed or sessile organisms, many in a stationary form although some are capable of slow primitive movement. While invertebrates lack physical defences such as a protective shell or spines, they are often rich in defence metabolites that can be utilized to attack prey or defend a habitat.

This review focused on a class of secondary defence metabolites abundant in marine invertebrates, five-carbon isoprenoid-derived terpenes. Extensive speciation from microorganisms to mammals can be attributed, at least in part to a wide range of temperatures (0 to 35 °C in arctic waters versus hydrothermal vents, respectively), pressures (1--1000 atm.), nutrient availabilities (oligotrophic to eutrophic) and lighting conditions that exist in this marine biome \[[@B6-marinedrugs-13-03154]\]. The analysis will be limited to the Red Sea which is considered an epicenter for marine biodiversity with an extremely high endemic biota including over 50 genera of hermatypic coral. Indeed soft coral (Cnidaria: Anthozoa: Octocorallia), which are an important structural component of coral reef communities \[[@B7-marinedrugs-13-03154],[@B8-marinedrugs-13-03154]\], are approximately 40% native to the Red Sea \[[@B6-marinedrugs-13-03154]\]. The Red Sea, in which extensive reef formation occurs, is arguably the world's warmest (up to 35 °C in summer) and most saline habitat (*ca*. 40 psu in the northern Red Sea) \[[@B6-marinedrugs-13-03154]\]. Despite the Red Sea's size and diversity of reef-associated inhabitants (for examples, see [Figure 1](#marinedrugs-13-03154-f001){ref-type="fig"}), marine invertebrates in this ecosystem remain poorly studied compared to other large coral reef systems around the world such as the Great Barrier Reef or the Caribbean. This review will cover terpenes isolated from marine invertebrates of the Red Sea ([Figure 2](#marinedrugs-13-03154-f002){ref-type="fig"}) as well as identified biological activities for compounds reported during the time period from 1980 to 2014.

![Samples of marine invertebrate diversity from the Red Sea including (from left to right starting at the top left corner) *Sarcophyton glaucum*, *S. regulare*, *S. ehrenbergi*, *Nephthea molle*, *Acropora humilis*, *Porites solida*, *Pocillopora verrucosa*, *Clothraria rubrinoidis* and *Cystoseira trinode*. Marine species exhibit greater phyta diversity than land species.](marinedrugs-13-03154-g001){#marinedrugs-13-03154-f001}

![Terpene skeletal types including ylangene (A), aromadendrane (B), tricycle-\[6,7,5\]-sesquiterpene (C), cembrane (D), xeniolide and xeniaphyllane (E), eunicellin diterpene (F), sesterterpene (G), norsesterterpene (H), triterpene (I) and steroid (J) types.](marinedrugs-13-03154-g002){#marinedrugs-13-03154-f002}

2. Sesquiterpenes
=================

Sesquiterpenes are secondary metabolites present in many marine organisms including soft coral (*e.g*., *Dendronephthya* sp., *Sinularia gardineri*, *Litophyton arboreum*, *Sarcophyton trocheliophorum*, *S. glaucum* and *Parerythropodium fulvum fulvum*) \[[@B9-marinedrugs-13-03154],[@B10-marinedrugs-13-03154],[@B11-marinedrugs-13-03154],[@B12-marinedrugs-13-03154],[@B13-marinedrugs-13-03154],[@B14-marinedrugs-13-03154]\], and sponges (*e.g*., *Hyrtios* sp. and *Diacarnus erythraenus*) \[[@B15-marinedrugs-13-03154],[@B16-marinedrugs-13-03154]\].

2.1. Ylangene-Type Sesquiterpenes
---------------------------------

Tricyclo-\[4,6,6\]-sesquiterpenes, Dendronephthol A--C (**1**--**3**) have been isolated from the soft coral *Dendronephthya*, family *Nephtheidae* ([Figure 3](#marinedrugs-13-03154-f003){ref-type="fig"}). Cytotoxic activity was observed for **1** and **3** against the murine lymphoma L5187Y cancer cell line with ED~50~ values of 8.4 and 6.8 μg/mL, respectively \[[@B9-marinedrugs-13-03154]\].

![Representative structures of ylangene-type sesquiterpenes (**1**--**3**).](marinedrugs-13-03154-g003){#marinedrugs-13-03154-f003}

2.2. Aromadendrane-Type Sesquiterpenes
--------------------------------------

Bicyclico \[[@B5-marinedrugs-13-03154],[@B7-marinedrugs-13-03154]\] sesquiterpenes have been isolated from several different coral with examples shown in [Table 1](#marinedrugs-13-03154-t001){ref-type="table"} and [Figure 4](#marinedrugs-13-03154-f004){ref-type="fig"}. Cytotoxicity to murine leukemia (P-388), human lung carcinoma (A-549), human colon carcinoma (HT-29), and human melanoma cells (MEL-28) \[[@B11-marinedrugs-13-03154]\] was observed with exposure to **4**. Inhibitory activity against HIV-1 protease (PR) at an IC~50~ of 7 μM was observed for **5**. Compounds **5** and **8** demonstrated cytostatic action with assaying HeLa cells, revealing potential use in virostatic cocktails \[[@B11-marinedrugs-13-03154]\]. Antitumor activity against lymphoma and Ehrlich cell lines was observed for **9** with LD~50~ in the range of 2.5--3.8 μM; antibacterial and antifungal activities were also observed \[[@B12-marinedrugs-13-03154]\]. Compound **10** showed potent activity against the prostate cancer line PC-3 with an IC~50~ of 9.3 ± 0.2 μM. Anti-proliferative activity of **9** can be attributed, at least in part, to its ability to induce cellular apoptosis \[[@B13-marinedrugs-13-03154]\]. Compound **12** exhibited a promising IC~50~ \> 1 μg/mL against three cancer cell lines including murine leukemia (P-388; ATCC: CCL-46), human lung carcinoma (A-549; ATCC: CCL-8) and human colon carcinoma (HT-29; ATCC: HTB-38) \[[@B15-marinedrugs-13-03154]\].

marinedrugs-13-03154-t001_Table 1

###### 

Aromadendrane sesquiterpenes, sources and activities.

  No.   Name                                                       Sources                            Activities
  ----- ---------------------------------------------------------- ---------------------------------- ------------------------------------------
  4     Guaianediol \[[@B10-marinedrugs-13-03154]\]                *Sinularia gardineri*              anti-tumor
  5     Alismol \[[@B11-marinedrugs-13-03154]\]                    *Litophyton arboreum*              cytostatic
  6     Lactiflorenol \[[@B17-marinedrugs-13-03154]\]              *Sinularia polydactyla*            
  7     10-*O*-Methyl alismoxide \[[@B11-marinedrugs-13-03154]\]   *L. arboreum*                      
  8     Alismoxide \[[@B11-marinedrugs-13-03154]\]                 *L. arboreum*                      cytostatic
  9     Palustrol \[[@B12-marinedrugs-13-03154]\]                  *Sarcophyton trocheliophorum*      anti-tumor, antibacterial and antifungal
  10    10(14)-Aromadendrene \[[@B13-marinedrugs-13-03154]\]       *Sarcophyton glaucum*              anti-tumor, antiproliferative
  11    Fulfulvene \[[@B14-marinedrugs-13-03154]\]                 *Parerythropodium fulvum fulvum*   
  12    *O*-Methyl guaianediol \[[@B15-marinedrugs-13-03154]\]     *Diacarnus erythraenus*            cytotoxic

![Representative structures of aromadendrane-type sesquiterpenes (**4**--**12**).](marinedrugs-13-03154-g004){#marinedrugs-13-03154-f004}

2.3. γ-Methoxybutenolide-Type Sesquiterpenes
--------------------------------------------

Tricyclo-\[6,7,5\]-sesquiterpenes, Hyrtiosenolide A and B have been isolated from the sponge *Hyrtios* sp., and compounds **13** and **14** exhibit weak antibacterial activity against *Escherichia coli* \[[@B16-marinedrugs-13-03154]\] ([Figure 5](#marinedrugs-13-03154-f005){ref-type="fig"}).

2.4. Miscellaneous Sesquiterpenes
---------------------------------

Additional sesquiterpenes have been isolated from several coral genera with examples reported in [Table 2](#marinedrugs-13-03154-t002){ref-type="table"} and [Figure 5](#marinedrugs-13-03154-f005){ref-type="fig"}. Compound **28** exhibits cytotoxic activity against human hepatocarcinoma (HepG2) and breast adenocarcinoma (MCF-7) \[[@B17-marinedrugs-13-03154]\].

marinedrugs-13-03154-t002_Table 2

###### 

Other sesquiterpenes, sources and activities.

  No.   Name                                                                                                            Sources                            Activities
  ----- --------------------------------------------------------------------------------------------------------------- ---------------------------------- --------------------------------
  15    5-Hydroxy-8-methoxy-calamenene \[[@B14-marinedrugs-13-03154]\]                                                  *Parerythropodium fulvum fulvum*   
  16    5-Hydroxy-8-methoxy-calamenene-6-al \[[@B14-marinedrugs-13-03154]\]                                             *Parerythropodium fulvum fulvum*   
  17    Peyssonol A \[[@B17-marinedrugs-13-03154]\]                                                                     *Peyssonnelia* sp.                 
  18    Ilimaquinone \[[@B18-marinedrugs-13-03154]\]                                                                    *Smenospongia* sp.                 
  19    Avarol \[[@B18-marinedrugs-13-03154],[@B19-marinedrugs-13-03154]\]                                              *Dysidea cinerea*                  HIV
  20    3′-Hydroxyavarone \[[@B20-marinedrugs-13-03154]\]                                                               *D.cinerea*                        
  21    3′,6′-Dihydroxyavarone \[[@B20-marinedrugs-13-03154]\]                                                          *D.cinerea*                        
  22    6′-Acetoxyavarone \[[@B20-marinedrugs-13-03154]\]                                                               *D.cinerea*                        
  23    6′- Hydroxy4′-methoxyavarone \[[@B20-marinedrugs-13-03154]\]                                                    *D.cinerea*                        
  24    6′-Hydroxyavarol \[[@B20-marinedrugs-13-03154]\]                                                                *D.cinerea*                        
  25    6′-Acetoxyavarol \[[@B20-marinedrugs-13-03154]\]                                                                *D.cinerea*                        
  26    Smenotronic acid \[[@B18-marinedrugs-13-03154]\]                                                                *Smenospongia* sp.                 
  27    Dactyltronic acids \[[@B18-marinedrugs-13-03154]\]                                                              *Smenospongia* sp.                 
  28    (*E*)-Methyl-3-(5-butyl-1-hydroxy-2,3-dimethyl-4-oxocyclopent-2-enyl)acrylate \[[@B21-marinedrugs-13-03154]\]   *Sarcophyton ehrenbergi*           cytotoxic (HepG2) (anti-tumor)

![Structures of sesquiterpenes-γ-methoxybutenolides and sesquiterpene derivatives (**13**--**28**).](marinedrugs-13-03154-g005){#marinedrugs-13-03154-f005}

3. Diterpenes
=============

Diterpenoids are widespread in various marine organisms including soft coral (*Sarcophyton glaucum*, *S. trocheliophorum*, *Sinularia polydactyla*, *S. gardineri*, *Litophyton arboreum*, *Lobophyton* sp., *Xenia* sp. and *Cladiella pachyclados*) \[[@B10-marinedrugs-13-03154],[@B11-marinedrugs-13-03154],[@B12-marinedrugs-13-03154],[@B13-marinedrugs-13-03154],[@B22-marinedrugs-13-03154],[@B23-marinedrugs-13-03154],[@B24-marinedrugs-13-03154],[@B25-marinedrugs-13-03154],[@B26-marinedrugs-13-03154],[@B27-marinedrugs-13-03154],[@B28-marinedrugs-13-03154],[@B29-marinedrugs-13-03154]\], and sponges (*Leucetta chagosensis*) \[[@B23-marinedrugs-13-03154]\].

3.1. Cembrane-Based Diterpenes
------------------------------

Fourteen-membered cyclic and bicycle-\[5,14\]-diterpenes have been isolated from numerous coral genera with examples shown in [Table 3](#marinedrugs-13-03154-t003){ref-type="table"} and [Figure 6](#marinedrugs-13-03154-f006){ref-type="fig"}. Compounds **29**, **41** and **42** exhibited antibacterial and antifungal activity against *Aspergillus flavus* and *Candida albicans* with low μM MIC values \[[@B12-marinedrugs-13-03154]\]. Lack of cytotoxicity against monkey kidney CV-1 cells suggests that **30**, **32**, and **33** may prove to be good candidate drugs against melanoma and warrant further studies in the development as antitumor agents \[[@B19-marinedrugs-13-03154]\]. Compound **30** exhibits moderate antifungal activity against *Cryptococcus neoformans* with an IC~50~ of 20 μg/mL \[[@B22-marinedrugs-13-03154]\]. Compound **43** showed selective cytotoxicity against HepG2 (IC~50~ 1.0 μg/mL) \[[@B24-marinedrugs-13-03154]\]. Compounds **44** and **45** were found to be inhibitors of cytochrome P~450~ 1A activity \[[@B25-marinedrugs-13-03154]\]. Compound **47** exhibits cytotoxic activity against HepG2, HCT-116, and HeLa cells with low IC~50~ μg/mL values \[[@B26-marinedrugs-13-03154]\]. Cytotoxic activity against human hepatocarcinoma (HepG2) and breast adenocarcinoma (MCF-7) cell lines was observed for **48** and **49** \[[@B21-marinedrugs-13-03154]\].

Compounds **66** and **68** have significant cytotoxic activity against the human hepatocellular liver carcinoma cell line HepG2 with an IC~50~ of 20 μM while **67** and **68** show activity against the human breast adenocarcinoma cell line MCF-7, also with an IC~50~ in the low μM range. The anti-proliferative activity of **66** and **68** can be attributed, at least in part, to observed cellular apoptosis activity \[[@B13-marinedrugs-13-03154],[@B30-marinedrugs-13-03154]\]. Compound **70** exhibits cytotoxicity to a variety of cell lines including murine leukemia (P-388), human lung carcinoma (A-549), human colon carcinoma (HT-29) and human melanoma (MEL-28) \[[@B31-marinedrugs-13-03154]\].

marinedrugs-13-03154-t003_Table 3

###### 

Cembrane diterpenes, sources and activities.

  No.   Name                                                                                                           Source                          Activity
  ----- -------------------------------------------------------------------------------------------------------------- ------------------------------- ------------------------------------------------
  29    Cembrene-C \[[@B12-marinedrugs-13-03154]\]                                                                     *Sarcophyton trocheliophorum*   anti-fungal, anti-bacterial
  30    Sarcophine \[[@B19-marinedrugs-13-03154],[@B22-marinedrugs-13-03154]\]                                         *S. glaucum*                    anti-tumor, antifungal
  31    (+)-7α,8β-Dihydroxydeepoxy-sarcophine \[[@B22-marinedrugs-13-03154]\]                                          *S. glaucum*                    
  32    Sarcophytolide 1 \[[@B19-marinedrugs-13-03154],[@B30-marinedrugs-13-03154]\]                                   *S. glaucum*                    anti-tumor
  33    (1*S*,2*E*,4*R*,7*E*,11*E*,13*S*)-Cembratrien-4,13-diol \[[@B22-marinedrugs-13-03154]\]                        *S. glaucum*                    anti-tumor
  34    (1*S*,2*E*,4*R*,6*E*,8*R*,11*S*,12*R*)-8,12-Epoxy-2,6-cembradiene-4,11-diol \[[@B22-marinedrugs-13-03154]\]    *S. glaucum*                    anti-tumor
  35    (1*S*,2*E*,4*R*,6*E*,8*S*,11*R*,12*S*)-8,11-Epoxy-4,12-epoxy-2,6-cembradiene \[[@B22-marinedrugs-13-03154]\]   *S. glaucum*                    anti-tumor
  36    Trochelioid A \[[@B23-marinedrugs-13-03154]\]                                                                  *S. trocheliophorum*            
  37    Trochelioid B \[[@B23-marinedrugs-13-03154]\]                                                                  *S. trocheliophorum*            
  38    16-Oxosarcophytonin E \[[@B23-marinedrugs-13-03154]\]                                                          *S. trocheliophorum*            
  39    *ent*-Sarcophine \[[@B23-marinedrugs-13-03154]\]                                                               *S. trocheliophorum*            
  40    8-*epi*-Sarcophinone \[[@B23-marinedrugs-13-03154]\]                                                           *S. trocheliophorum*            
  41    Sarcotrocheliol acetate \[[@B12-marinedrugs-13-03154]\]                                                        *S. trocheliophorum*            anti-tumor
  42    Sarcotrocheliol \[[@B12-marinedrugs-13-03154]\]                                                                *S. trocheliophorum*            anti-tumor
  43    Durumolide C \[[@B24-marinedrugs-13-03154]\]                                                                   *Sinularia polydactyla*         anti-fungal, anti-bacterial
  44    11(*S*)-Hydroperoxylsarcoph-12(20)-ene \[[@B22-marinedrugs-13-03154]\]                                         *S. glaucum*                    anti-fungal, anti-bacterial
  45    12(*S*)-Hydroperoxylsarcoph-10-ene \[[@B25-marinedrugs-13-03154]\]                                             *S. glaucum*                    cytotoxic HepG2 (anti-tumor)
  46    (2*R*,7*R*,8*R*)-Dihydroxy-deepoxysarcophine \[[@B26-marinedrugs-13-03154]\]                                   *S. glaucum*                    anti-tumor
  47    7β-Acetoxy-8α-hydroxy-deepoxysarcophine \[[@B26-marinedrugs-13-03154]\]                                        *S. glaucum*                    cytotoxic (HepG2)( anti-tumor)
  48    7-Keto-8α-hydroxy-deepoxysarcophine \[[@B21-marinedrugs-13-03154]\]                                            *S. ehrenbergi*                 cytotoxic (HepG2) (anti-tumor)
  49    7β-Chloro-8α-hydroxy-12-acetoxy-deepoxysarcophine \[[@B21-marinedrugs-13-03154]\]                              *S. ehrenbergi*                 cytotoxic (HepG2) (anti-tumor)
  50    Nephthenol \[[@B27-marinedrugs-13-03154]\]                                                                     *Lobophytum pauciflorum*        
  51    Cembrene-A \[[@B27-marinedrugs-13-03154]\]                                                                     *Alcyonium utinomii*            
  52    Alcyonol A \[[@B27-marinedrugs-13-03154]\]                                                                     *A. utinomii*                   
  53    Alcyonol B \[[@B27-marinedrugs-13-03154]\]                                                                     *A. utinomii*                   
  54    Alcyonol C \[[@B27-marinedrugs-13-03154]\]                                                                     *A. utinomii*                   
  55    Pauciflorol A \[[@B27-marinedrugs-13-03154]\]                                                                  *L. pauciflorum*                
  56    Pauciflorol B \[[@B27-marinedrugs-13-03154]\]                                                                  *L. pauciflorum*                
  57    Thunbergol \[[@B27-marinedrugs-13-03154]\]                                                                     *L. pauciflorum*                
  58    Labolide \[[@B27-marinedrugs-13-03154]\]                                                                       *L. crassum*                    
  59    20-Acetylsinularolide B \[[@B27-marinedrugs-13-03154]\]                                                        *L. crassum*                    
  60    20-Acetylsinularolide C \[[@B27-marinedrugs-13-03154]\]                                                        *L. crassum*                    
  61    Sinularolide C \[[@B27-marinedrugs-13-03154]\]                                                                 *L. crassum*                    
  62    Sinularolide C diacetate \[[@B27-marinedrugs-13-03154]\]                                                       *L. crassum*                    
  63    3-Deoxypresinularolide B \[[@B27-marinedrugs-13-03154]\]                                                       *L. crassum*                    
  64    3-Deoxy-20-acetylpresinularolide B \[[@B27-marinedrugs-13-03154]\]                                             *L. crassum*                    
  65    Sarcophytol M \[[@B11-marinedrugs-13-03154]\]                                                                  *Litophyton arboreum*           
  66    Sarcophytolol \[[@B13-marinedrugs-13-03154]\]                                                                  *Sarcophyton glaucum*           cytotoxic HepG2 (anti-tumor) antiproliferative
  67    Sarcophytolide B \[[@B13-marinedrugs-13-03154]\]                                                               *S. glaucum*                    
  68    Sarcophytolide C \[[@B13-marinedrugs-13-03154]\]                                                               *S. glaucum*                    
  69    Deoxosarcophine \[[@B13-marinedrugs-13-03154]\]                                                                *S. glaucum*                    cytotoxic against MCF-7 (anti-tumor)
  70    2-*epi*-Sarcophine \[[@B31-marinedrugs-13-03154]\]                                                             *S. auritum*                    cytotoxic
  71    (1*R*,2*E*,4*S*,6*E*,8*R*,11*R*,12*R*)-2,6-cembradiene-4,8,11,12-tetrol \[[@B31-marinedrugs-13-03154]\]        *S. auritum*                    cytotoxic
  72    Singardin \[[@B31-marinedrugs-13-03154]\]                                                                      *Sinularia gardineri*           anti-tumor

###### 

Structures of cembrane-based diterpenes (**29**--**72**).

![](marinedrugs-13-03154-g006a)

![](marinedrugs-13-03154-g006b)

3.2. Xenicane Diterpenes
------------------------

Bicyclo-\[6,9\]/\[4,9\]-diterpenes have been isolated from the coral genus *Xenia* with examples shown in [Table 4](#marinedrugs-13-03154-t004){ref-type="table"} and [Figure 7](#marinedrugs-13-03154-f007){ref-type="fig"}.

marinedrugs-13-03154-t004_Table 4

###### 

Xenia diterpenes, sources and activities.

  No.   Name                                                                 Source
  ----- -------------------------------------------------------------------- ------------------------------------
  73    Xenicin \[[@B28-marinedrugs-13-03154]\]                              *Xenia macrosoiculata*
  74    Xenialactol-D \[[@B28-marinedrugs-13-03154]\]                        *X. obscuronata*
  75    Xenialactol-C \[[@B28-marinedrugs-13-03154]\]                        *X. obscuronata*
  76    Xeniolide-E \[[@B28-marinedrugs-13-03154]\]                          *X. obscuronata*
  77    14(15)-Epoxyxeniaphyllene \[[@B28-marinedrugs-13-03154]\]            *X. lilielae*
  78    Xeniaphyllene-dioxide \[[@B28-marinedrugs-13-03154]\]                *X. lilielae*
  79    Xeniaphyllenol-C \[[@B28-marinedrugs-13-03154]\]                     *X. macrosoiculata*
  80    Epoxyxeniaphyllenol-A \[[@B28-marinedrugs-13-03154]\]                *X. lilielae*, *X. macrosoiculata*
  81    l4,15-Xeniaphyllandiol-4,5-epoxide \[[@B28-marinedrugs-13-03154]\]   *X. macrosoiculata*
  82    Xeniaphyllenol-B \[[@B28-marinedrugs-13-03154]\]                     *X. macrosoiculata*

![The structures of *Xenicane* diterpenes (**73**--**82**).](marinedrugs-13-03154-g007){#marinedrugs-13-03154-f007}

3.3. Eunicellin-Based Diterpenes
--------------------------------

Tricyclo-\[6,5,10\]-diterpenes have been isolated from the soft coral genus *Cladiella* with examples shown in [Table 5](#marinedrugs-13-03154-t005){ref-type="table"} and [Figure 8](#marinedrugs-13-03154-f008){ref-type="fig"}. Eunicellin-based diterpenes display a wide range of bioactivities including anti-inflammatory and antitumor activities \[[@B26-marinedrugs-13-03154]\]. Compounds **83**--**104** have been evaluated for activity to inhibit growth, proliferation, invasion and migration of a prostate cancer cell line with potent anti-migratory and anti-invasive activities observed. Compounds with exomethylene functionalities at C-7 and C-11 demonstrate low anti-migratory activity, however replacement of the exomethylene moiety at C-7 with a quaternary oxygenated carbon, appreciatively increases the activity, as observed for compounds **93**--**94** and **96** \[[@B29-marinedrugs-13-03154]\].

3.4. Miscellaneous Diterpenes
-----------------------------

Miscellaneous diterpenes were isolated from three different genus *Xenia*, *Chelonaplysilla* and *Dysidea*. These compounds were classified as: prenylated germacrenes (**105**), bicyclic diterpenes (**108**, **109**), clerodane diterpenes (**107**), carbo-tricyclic diterpenes (**108**) and re-arranged spongian diterpenes (**110**--**113**) as shown in [Table 6](#marinedrugs-13-03154-t006){ref-type="table"} and [Figure 9](#marinedrugs-13-03154-f009){ref-type="fig"}.

marinedrugs-13-03154-t005_Table 5

###### 

Eunicellin diterpenoids, sources and activities.

  No.   Name                                                              Source                    Activity
  ----- ----------------------------------------------------------------- ------------------------- ---------------------------
  83    Pachycladin A \[[@B29-marinedrugs-13-03154]\]                     *Cladiella pachyclados*   anti-tumor, anti-invasive
  84    Klysimplexin G \[[@B29-marinedrugs-13-03154]\]                    *C. pachyclados*          anti-tumor, anti-invasive
  85    Pachycladin B \[[@B29-marinedrugs-13-03154]\]                     *C. pachyclados*          anti-tumor, anti-invasive
  86    Klysimplexin E \[[@B29-marinedrugs-13-03154]\]                    *C. pachyclados*          anti-tumor, anti-invasive
  87    Pachycladin C \[[@B29-marinedrugs-13-03154]\]                     *C. pachyclados*          anti-tumor, anti-invasive
  88    Cladiellisin \[[@B29-marinedrugs-13-03154]\]                      *C. pachyclados*          anti-tumor, anti-invasive
  89    3-Acetyl cladiellisin \[[@B29-marinedrugs-13-03154]\]             *C. pachyclados*          anti-tumor, anti-invasive
  90    3,6-Diacetyl cladiellisin \[[@B29-marinedrugs-13-03154]\]         *C. pachyclados*          anti-tumor, anti-invasive
  91    Pachycladin D \[[@B29-marinedrugs-13-03154]\]                     *C. pachyclados*          anti-tumor, anti-invasive
  92    Pachycladin E \[[@B26-marinedrugs-13-03154]\]                     *C. pachyclados*          anti-tumor, anti-invasive
  93    Sclerophytin A \[[@B29-marinedrugs-13-03154]\]                    *C. pachyclados*          anti-tumor, anti-invasive
  94    Sclerophytin F methyl ether \[[@B29-marinedrugs-13-03154]\]       *C. pachyclados*          anti-tumor, anti-invasive
  95    Sclerophytin B \[[@B29-marinedrugs-13-03154]\]                    *C. pachyclados*          anti-tumor, anti-invasive
  96    (+)-Polyanthelin A \[[@B29-marinedrugs-13-03154]\]                *C. pachyclados*          anti-tumor, anti-invasive
  97    Cladiella-6*Z*,11(17)-dien-3-ol \[[@B29-marinedrugs-13-03154]\]   *C. pachyclados*          anti-tumor, anti-invasive
  98    Briarein A \[[@B32-marinedrugs-13-03154]\]                        *Junceella juncea*        
  99    Juncins A \[[@B32-marinedrugs-13-03154]\]                         *J. juncea*               
  100   Juncins B \[[@B32-marinedrugs-13-03154]\]                         *J. juncea*               
  101   Juncins C \[[@B32-marinedrugs-13-03154]\]                         *J. juncea*               
  102   Juncins D \[[@B32-marinedrugs-13-03154]\]                         *J. juncea*               
  103   Juncins E \[[@B32-marinedrugs-13-03154]\]                         *J. juncea*               
  104   Juncins \[[@B32-marinedrugs-13-03154]\]                           *J. juncea*               

![The structure of eunicellin-type diterpenes (**83**--**104**).](marinedrugs-13-03154-g008){#marinedrugs-13-03154-f008}

marinedrugs-13-03154-t006_Table 6

###### 

Macrocyclic diterpenes, sources and activities.

  No.   Name                                                                                     Source
  ----- ---------------------------------------------------------------------------------------- --------------------------
  105   Obscuronatin \[[@B28-marinedrugs-13-03154]\]                                             *Xenia obscuronata*
  106   Biflora-4,10(19),15-triene \[[@B28-marinedrugs-13-03154],[@B33-marinedrugs-13-03154]\]   *X. obscuronata*
  107   Chelodane \[[@B34-marinedrugs-13-03154]\]                                                *Chelonaplysilla erecta*
  108   Barekoxide \[[@B34-marinedrugs-13-03154]\]                                               *C. erecta*
  109   Zaatirin \[[@B34-marinedrugs-13-03154]\]                                                 *C. erecta*
  110   Norrisolide \[[@B35-marinedrugs-13-03154]\]                                              *Dysidea* sp.
  111   Norrlandin \[[@B35-marinedrugs-13-03154]\]                                               *Dysidea* sp.
  112   Seco-norrlandin B \[[@B35-marinedrugs-13-03154]\]                                        *Dysidea* sp.
  113   Seco-norrlandin C \[[@B35-marinedrugs-13-03154]\]                                        *Dysidea* sp.

![The structure of the macrocyclic type diterpenes (**105**--**113**).](marinedrugs-13-03154-g009){#marinedrugs-13-03154-f009}

4. Sesterterpenes and Norsesterterpenes
=======================================

4.1. Sesterterpenes
-------------------

Pentacyclo-\[6,6,6,6,5\]-sesterterpenes have been isolated from two different sponges with examples shown in [Table 7](#marinedrugs-13-03154-t007){ref-type="table"} and [Figure 10](#marinedrugs-13-03154-f010){ref-type="fig"}. Compound **116** exhibits antimycobacterial inhibition against *Mycobacterium tuberculosis* (H37Rv) at a concentration of 6 μg/mL while **117**--**119** displayed moderate to weak inhibitory activity \[[@B36-marinedrugs-13-03154]\]. Compounds **122**--**123** showed significant cytotoxicity against murine leukemia (P-388), human lung carcinoma (A-549) and a human colon carcinoma (HT-29) \[[@B37-marinedrugs-13-03154]\].
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###### 

Sesterterpenes, sources and activities.

  No.   Name                                                                      Source               Activity
  ----- ------------------------------------------------------------------------- -------------------- ------------------------------
  114   Scalardysin \[[@B18-marinedrugs-13-03154]\]                               *Dysidea herbacea*   
  115   25-Dehydroxy-12- *epi*-deacetylscalarin \[[@B36-marinedrugs-13-03154]\]   *Hyrtios erecta*     antimycobacterial
  116   Sesterstatin \[[@B36-marinedrugs-13-03154]\]                              *H. erecta*          antimycobacterial
  117   16-*epi*-Scalarolbutenolide \[[@B36-marinedrugs-13-03154]\]               *H. erecta*          antimycobacterial
  118   3-Acetylsesterstatin \[[@B36-marinedrugs-13-03154]\]                      *H. erecta*          antimycobacterial
  119   Salmahyrtisol A \[[@B37-marinedrugs-13-03154]\]                           *H. erecta*          
  120   Hyrtiosal \[[@B37-marinedrugs-13-03154]\]                                 *H. erecta*          
  121   Salmahyrtisol B \[[@B37-marinedrugs-13-03154]\]                           *H. erecta*          cytotoxic (anti-tumor)
  122   19-Acetyl sesterstatin \[[@B37-marinedrugs-13-03154]\]                    *H. erecta*          cytotoxic (anti-tumor)
  123   Scalarolide \[[@B37-marinedrugs-13-03154]\]                               *H. erecta*          
  124   Salmahyrtisol C \[[@B37-marinedrugs-13-03154]\]                           *H. erecta*          
  125   16-Hydroxyscalarolide \[[@B38-marinedrugs-13-03154]\]                     *H. erecta*          Cytotoxic, antimycobacterial
  126   12-*O*-Deacetyl-12-*epi*-scalarine \[[@B38-marinedrugs-13-03154]\]        *H. erecta*          Cytotoxic, antimycobacterial
  127   (−)-Wistarin \[[@B39-marinedrugs-13-03154]\]                              *Ircinia wistarii*   
  128   (+)-Wistarin \[[@B39-marinedrugs-13-03154]\]                              *I. wistarii*        
  129   (−)-Ircinianin \[[@B39-marinedrugs-13-03154]\]                            *I.* *wistarii*      
  130   Bilosespens A \[[@B40-marinedrugs-13-03154]\]                             *Dysidea cinerea*    Cytotoxic
  131   Bilosespens A \[[@B40-marinedrugs-13-03154]\]                             *D. cinerea*         Cytotoxic

###### 

Structures of sesterterpenes (**114**--**131**).

![](marinedrugs-13-03154-g010a)

![](marinedrugs-13-03154-g010b)

4.2. Norsesterterpenes
----------------------

Norsesterterpenes have been isolated from the sponge species *Diacarnus erythraeanus* with examples shown in [Table 8](#marinedrugs-13-03154-t008){ref-type="table"} and [Figure 11](#marinedrugs-13-03154-f011){ref-type="fig"}. Antitumor natural peroxide products are known to induce cytotoxicity in cancer cells through the generation of particular reactive oxygen species (ROSs). Compounds **134**--**135** displayed mean IC~50~ growth inhibitions less than 10 μM with several tumor cell lines \[[@B41-marinedrugs-13-03154]\]. However, additional studies with **135** established no *in vitro* selective growth inhibition between normal and tumor cells. In assaying three cancer cells including murine leukemia (P-388), human lung carcinoma (A-549) and human colon carcinoma (HT-29), **140**--**143** exhibited an IC~50~ greater than 1 μg/mL \[[@B15-marinedrugs-13-03154]\] while **145** showed lower cytotoxicity against the same lines \[[@B42-marinedrugs-13-03154]\].
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###### 

Norsesterterpenes, sources and activities.

  No.   Name                                                                          Source                     Activity
  ----- ----------------------------------------------------------------------------- -------------------------- ------------------------
  132   Nuapapuin A methyl ester \[[@B41-marinedrugs-13-03154]\]                      *Diacarnus erythraeanus*   
  133   Methyl-2-epinuapapuanoate \[[@B41-marinedrugs-13-03154]\]                     *D. erythraeanus*          
  134   (−)-13,14-Epoxymuqubilin A \[[@B41-marinedrugs-13-03154]\]                    *D. erythraeanus*          anti-tumor
  135   (−)-9,10-Epoxymuqubilin A \[[@B41-marinedrugs-13-03154]\]                     *D. erythraeanus*          anti-tumor
  136   (−)-Muqubilin A \[[@B41-marinedrugs-13-03154],[@B43-marinedrugs-13-03154]\]   *D. erythraeanus*          anti-tumor
  137   Hurghaperoxide \[[@B41-marinedrugs-13-03154]\]                                *D. erythraeanus*          
  138   Sigmosceptrellin B \[[@B41-marinedrugs-13-03154]\]                            *D. erythraeanus*          
  139   Sigmosceptrellin B methyl ester \[[@B41-marinedrugs-13-03154]\]               *D. erythraeanus*          
  140   Aikupikoxide A \[[@B15-marinedrugs-13-03154]\]                                *D. erythraeanus*          cytotoxic
  141   Aikupikoxide D \[[@B15-marinedrugs-13-03154]\]                                *D. erythraeanus*          cytotoxic
  142   Aikupikoxide C \[[@B15-marinedrugs-13-03154]\]                                *D. erythraeanus*          cytotoxic
  143   Aikupikoxide B \[[@B15-marinedrugs-13-03154]\]                                *D. erythraeanus*          cytotoxic
  144   Tasnemoxide A \[[@B42-marinedrugs-13-03154]\]                                 *D. erythraeanus*          cytotoxic (anti-tumor)
  145   Tasnemoxide B \[[@B42-marinedrugs-13-03154]\]                                 *D. erythraeanus*          cytotoxic (anti-tumor)
  146   Tasnemoxide C \[[@B42-marinedrugs-13-03154]\]                                 *D. erythraeanus*          cytotoxic (anti-tumor)
  147   *epi*-Sigmosceptrellin B \[[@B44-marinedrugs-13-03154]\]                      *D. erythraeanus*          
  148   Muqubilone \[[@B45-marinedrugs-13-03154]\]                                    *D. erythraeanus*          antimalarial

![Structures of norterpenes (**132**--**148**).](marinedrugs-13-03154-g011){#marinedrugs-13-03154-f011}

5. Triterpenes
==============

Structurally diverse triterpenes are widespread in Red Sea sponges with examples shown in [Table 9](#marinedrugs-13-03154-t009){ref-type="table"} and [Figure 12](#marinedrugs-13-03154-f012){ref-type="fig"}. Compound **149** inhibits growth of human breast cancer cells, MDA-MB-231, MCF-7, BT-474 and T-47D, in a dose-dependent manner \[[@B46-marinedrugs-13-03154],[@B47-marinedrugs-13-03154]\]. Triterpenes have also been studied for their efficacy in reducing the appearance of drug resistance. In the presence of many cytotoxic drugs, resistant cell variants appear, a process referred to as multidrug resistance (MDR). Overexpression of the ATP-binding cassette (ABC) transporter ABCB1/P-glycoprotein (P-gp) is one of the most common causes of MDR in cancer cells. P-gp a 170-kD transmembrane glycoprotein functions as a drug efflux pump that extrudes a wide spectrum of compounds including amphipathic and hydrophobic drugs. Sipholane triterpenoids can serve as P-gp inhibitors and are being developed to enhance the effect of chemotherapeutic drugs with MDR cancer cells *in vitro* and *in vivo* \[[@B33-marinedrugs-13-03154],[@B36-marinedrugs-13-03154]\]. Compounds **162**--**163** enhanced cytotoxicity of several P-gp substrate-anticancer drugs, including colchicine, vinblastine and paclitaxel. These sipholane triterpenes significantly reversed the MDR-phenotype in P-gp-over expressing MDR cancer cells, KB-C2, in a dose-dependent manner. Moreover, these sipholanes have no effect on the response to cytotoxic agents in cells lacking P-gp expression or expressing MRP1 (ABCC1) or MRP7 (ABCC10) or with the breast cancer resistance protein (BCRP/ABCG2). Perhaps most importantly, these sipholanes with a low IC~50~ of *ca*. 50 μM are not toxic to the assayed cell lines \[[@B48-marinedrugs-13-03154]\].
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###### 

Triterpenes, sources and activities.

  No.   Name                                                                                                                                                                                                                        Source                        Activity
  ----- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------- ------------
  149   Neviotine-A \[[@B46-marinedrugs-13-03154],[@B47-marinedrugs-13-03154]\]                                                                                                                                                     *Siphonochalina siphonella*   
  150   Sipholenol A \[[@B47-marinedrugs-13-03154],[@B49-marinedrugs-13-03154],[@B50-marinedrugs-13-03154],[@B51-marinedrugs-13-03154],[@B52-marinedrugs-13-03154],[@B53-marinedrugs-13-03154]\]                                    *S. siphonella*               anti-tumor
  151   SipholenolA-4-*O*-3′,4′-dichlorobenzoate \[[@B49-marinedrugs-13-03154]\]                                                                                                                                                    *S. siphonella*               
  152   Shaagrockol B \[[@B54-marinedrugs-13-03154]\]                                                                                                                                                                               *Toxiclona toxius*            
  153   Shaagrockol C \[[@B54-marinedrugs-13-03154]\]                                                                                                                                                                               *T. toxius*                   
  154   Sipholenol G \[[@B55-marinedrugs-13-03154]\]                                                                                                                                                                                *S. siphonella*               
  155   Sipholenone D \[[@B55-marinedrugs-13-03154]\]                                                                                                                                                                               *S. siphonella*               
  156   Sipholenol F \[[@B55-marinedrugs-13-03154]\]                                                                                                                                                                                *S. siphonella*               
  157   Sipholenol H \[[@B55-marinedrugs-13-03154]\]                                                                                                                                                                                *S. siphonella*               
  158   Neviotine B \[[@B55-marinedrugs-13-03154]\]                                                                                                                                                                                 *S. siphonella*               
  159   Sipholenoside A \[[@B55-marinedrugs-13-03154]\]                                                                                                                                                                             *S. siphonella*               
  160   Sipholenoside B \[[@B55-marinedrugs-13-03154]\]                                                                                                                                                                             *S. siphonella*               
  161   Siphonellinol B \[[@B55-marinedrugs-13-03154]\]                                                                                                                                                                             *S. siphonella*               
  162   Dahabinone A \[[@B55-marinedrugs-13-03154]\]                                                                                                                                                                                *S. siphonella*               
  163   Sipholenone E \[[@B51-marinedrugs-13-03154]\]                                                                                                                                                                               *S. siphonella*               anti-tumor
  164   Sipholenol L \[[@B47-marinedrugs-13-03154],[@B51-marinedrugs-13-03154]\]                                                                                                                                                    *S. siphonella*               anti-tumor
  165   Sipholenol J \[[@B51-marinedrugs-13-03154]\]                                                                                                                                                                                *S. siphonella*               
  166   (2*S*,4a*S*,5*S*,6*R*,8a*S*)-5-(2-((1*S*,3a*S*,5*R*,8a*S*,*Z*)-1-hydroxy-1,4,4,6-tetramethyl-1,2,3,3a,4,5,8,8a-octahydroazulen-5-yl)-ethyl)-4a,6-dimethyloctahydro-2*H*-chromene-2,6-diol \[[@B51-marinedrugs-13-03154]\]   *S. siphonella*               
  167   Sipholenol K \[[@B51-marinedrugs-13-03154]\]                                                                                                                                                                                *S. siphonella*               
  168   Sipholenol M \[[@B51-marinedrugs-13-03154]\]                                                                                                                                                                                *S. siphonella*               
  169   Siphonellinol D \[[@B51-marinedrugs-13-03154]\]                                                                                                                                                                             *S. siphonella*               
  170   Siphonellinol E \[[@B51-marinedrugs-13-03154]\]                                                                                                                                                                             *S. siphonella*               
  171   Siphonellinol-C-23-hydroperoxide \[[@B51-marinedrugs-13-03154]\]                                                                                                                                                            *S. siphonella*               
  172   Siphonellinol C \[[@B56-marinedrugs-13-03154]\]                                                                                                                                                                             *S. siphonella*               
  173   *epi*-Sipholenol I \[[@B56-marinedrugs-13-03154]\]                                                                                                                                                                          *S. siphonella*               
  174   Sipholenol I \[[@B51-marinedrugs-13-03154]\]                                                                                                                                                                                *S. siphonella*               
  175   Sipholenone A \[[@B56-marinedrugs-13-03154],[@B47-marinedrugs-13-03154]\]                                                                                                                                                   *S. siphonella*               
  176   Sipholenol D \[[@B52-marinedrugs-13-03154]\]                                                                                                                                                                                *S. siphonella*               
  177   Neviotine-C \[[@B47-marinedrugs-13-03154]\]                                                                                                                                                                                 *Siphonochalina siphonella*   cytotoxic

###### 

Structures of triterpenes (**149**--**177**).
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6. Steroids
===========

Steriods are widespread throughout the marine biome with recent chemical reports including soft coral (*Sinularia candidula*, *S. polydactyla*, *Heteroxenia ghardaqensis*, *Dendronephthya* sp*.*, *Lobophytom depressum* and *Litophyton arboreum*) \[[@B9-marinedrugs-13-03154],[@B11-marinedrugs-13-03154],[@B24-marinedrugs-13-03154],[@B57-marinedrugs-13-03154],[@B58-marinedrugs-13-03154],[@B59-marinedrugs-13-03154],[@B60-marinedrugs-13-03154]\], black coral (*Antipathes dichotoma*) \[[@B38-marinedrugs-13-03154],[@B40-marinedrugs-13-03154]\], and sponges (*Echinoclathria gibbosa*, *Hyrtios* sp., *Erylus* sp., and *Petrosia* sp.) \[[@B18-marinedrugs-13-03154],[@B64-marinedrugs-13-03154],[@B65-marinedrugs-13-03154],[@B66-marinedrugs-13-03154]\]. Steroid examples are shown in [Table 10](#marinedrugs-13-03154-t010){ref-type="table"} and [Figure 13](#marinedrugs-13-03154-f013){ref-type="fig"}.
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###### 

Steroids, sources and activities.

  No.   Name                                                                                                                Source                       Activity
  ----- ------------------------------------------------------------------------------------------------------------------- ---------------------------- ------------------------
  178   3β-25-Dihydroxy-4-methyl-5α,8α-epidioxy-2-ketoergost-9-ene \[[@B57-marinedrugs-13-03154]\]                          *Sinularia candidula*        anti-viral
  179   Gorgosten-5(*E*)-3β-ol \[[@B58-marinedrugs-13-03154]\]                                                              *Heteroxenia ghardaqensis*   anti-tumor
  180   Gorgostan-3β,5α,6β,11α-tetraol (sarcoaldosterol A) \[[@B58-marinedrugs-13-03154]\]                                  *H. ghardaqensis*            
  181   Gorgostan-3β,5α,6β-triol-11α-acetate \[[@B58-marinedrugs-13-03154]\]                                                *H. ghardaqensis*            
  182   5α-Pregna-3β-acetoxy-12β,16β-diol-20-one \[[@B59-marinedrugs-13-03154]\]                                            *Echinoclathria gibbosa*     anti-tumor
  183   β-Sitosterol-3-*O*-(3*Z*)-pentacosenoate \[[@B59-marinedrugs-13-03154]\]                                            *E. gibbosa*                 anti-tumor
  184   Cholesterol \[[@B9-marinedrugs-13-03154]\]                                                                          *Dendronephthya*             
  185   Dendronesterone A \[[@B9-marinedrugs-13-03154]\]                                                                    *Dendronephthya*             
  186   24-Methylcholestane-3β,5α,6β,25-tetrol-25-monoacetate \[[@B24-marinedrugs-13-03154]\]                               *Sinularia polydactyla*      anti-tumor
  187   24-Methylcholestane-5-en-3β,25-diol \[[@B24-marinedrugs-13-03154]\]                                                 *S. polydactyla*             antimicrobial
  188   Lobophytosterol \[[@B60-marinedrugs-13-03154]\]                                                                     *L. depressum*               
  189   5β,6β-Epoxy-24*E*-methylchloestan-3β,22(*R*),25-triol \[[@B60-marinedrugs-13-03154]\]                               *L. depressum*               
  190   Depresosterol \[[@B60-marinedrugs-13-03154]\]                                                                       *L. depressum*               
  191   (22*R*,24*E*,28*E*)-5β,6β-Epoxy-22,28-oxido-24-methyl-5α-cholestan-3β,25,28-triol \[[@B60-marinedrugs-13-03154]\]   *L. depressum*               
  192   (22*R*,24*E*)-24-Methylcholest-5-en-3β,22,25,28-tetraol \[[@B60-marinedrugs-13-03154]\]                             *L. depressum*               
  193   24-Methylcholesta-5,24(28)-diene-3β-ol \[[@B11-marinedrugs-13-03154]\]                                              *Litophyton arboreum*        
  194   7β-Acetoxy-24-methylcholesta-5-24(28)-diene-3,19-diol \[[@B11-marinedrugs-13-03154]\]                               *L. arboreum*                cytotoxic
  195   24-Methylcholesta-5,24(28)-diene-3β,7β,19-triol \[[@B11-marinedrugs-13-03154]\]                                     *L. arboreum*                
  196   Hyrtiosterol \[[@B16-marinedrugs-13-03154]\]                                                                        *Hyrtios* Species            
  197   Eryloside A \[[@B61-marinedrugs-13-03154],[@B62-marinedrugs-13-03154],[@B63-marinedrugs-13-03154]\]                 Genus *Erylus*               cytotoxic
  198   (22*E*)-Methylcholesta-5,22-diene-1α,3β,7α-triol \[[@B64-marinedrugs-13-03154]\]                                    *Antipathes dichotoma*       anti-bacterial
  199   3β,7α-Dihydroxy-cholest-5-ene \[[@B64-marinedrugs-13-03154]\]                                                       *A. dichotoma*               anti-bacterial
  200   (22*E*,24*S*)-5α,8α-Epidioxy-24 methylcholesta -6,22-dien-3β-ol \[[@B64-marinedrugs-13-03154]\]                     *A. dichotoma*               anti-bacterial
  201   (22*E*,24*S*)-5α,8α-Epidioxy-24-methylcholesta-6,9(11),22-trien-3β-ol \[[@B64-marinedrugs-13-03154]\]               *A. dichotoma*               anti-bacterial
  202   3β-Hexadecanoylcholest-5-en-7-one \[[@B65-marinedrugs-13-03154]\]                                                   *A. dichotoma*               anti-tumor
  203   3β-Hexadecanoylcholest-5-en-7β-ol \[[@B65-marinedrugs-13-03154]\]                                                   *A. dichotoma*               anti-tumor
  204   Cholest-5-en-3β-yl-formate \[[@B65-marinedrugs-13-03154]\]                                                          *A. dichotoma*               anti-tumor
  205   3β-Hydroxycholest-5-en-7-one \[[@B65-marinedrugs-13-03154]\]                                                        *A. dichotoma*               
  206   Cholest-5-en-3β,7β-diol \[[@B65-marinedrugs-13-03154]\]                                                             *A. dichotoma*               
  207   22-Dehydrocholestrol \[[@B65-marinedrugs-13-03154]\]                                                                *A. dichotoma*               
  208   3β,7β,9α-Trihydroxycholest-5-en \[[@B66-marinedrugs-13-03154]\]                                                     *Petrosia*                   cytotoxic (anti-tumor)
  209   Cholest-5-en-7β-methyl-3β-yl formate \[[@B66-marinedrugs-13-03154]\]                                                *Petrosia* sp*.*             cytotoxic (anti-tumor)
  210   Dehydroepiandrosterone \[[@B66-marinedrugs-13-03154]\]                                                              *Petrosia* sp.               cytotoxic (anti-tumor)
  211   7-Dehydrocholesterol \[[@B66-marinedrugs-13-03154]\]                                                                *Petrosia* sp.               cytotoxic (anti-tumor)
  212   5α,6α*-*Epoxycholest-8(14)-ene-3β,7α-diol \[[@B66-marinedrugs-13-03154]\]                                           *Petrosia* sp.               cytotoxic (anti-tumor)
  213   5α,8α-Epidioxycholesta-6-en-3β-ol \[[@B66-marinedrugs-13-03154]\]                                                   *Petrosia* sp.               cytotoxic (anti-tumor)
  214   Cholesta-8-en-3β,5α,6α,25-tetrol \[[@B67-marinedrugs-13-03154]\]                                                    *Lamellodysidea herbacea*    
  215   Cholesta-8(14)-en-3β,5α,6α,25-tetrol \[[@B67-marinedrugs-13-03154]\]                                                *L. herbacea*                
  216   Cholesta-8,24-dien-3β,5α,6α-triol \[[@B67-marinedrugs-13-03154]\]                                                   *L. herbacea*                anti-fungal
  217   Cholesta-8(14),24-dien-3β,5α,6α-triol \[[@B67-marinedrugs-13-03154]\]                                               *L. herbacea*                anti-fungal
  218   Clathsterol \[[@B68-marinedrugs-13-03154]\]                                                                         *Clathria* sp.               
  219   Clionasterol \[[@B69-marinedrugs-13-03154]\]                                                                        *Dragmacidon coccinea*       
  220   Stigmasterol \[[@B69-marinedrugs-13-03154]\]                                                                        *D. coccinea*                
  221   Campesterol \[[@B69-marinedrugs-13-03154]\]                                                                         *D. coccinea*                
  222   Brassicasterol \[[@B69-marinedrugs-13-03154]\]                                                                      *D. coccinea*                
  223   Dendrotriol \[[@B70-marinedrugs-13-03154]\]                                                                         *Dendronephthya hemprichi*   
  224   Erylosides K \[[@B62-marinedrugs-13-03154]\]                                                                        *Erylus lendenfeldi*         
  225   Erylosides L \[[@B62-marinedrugs-13-03154]\]                                                                        *E. lendenfeldi*             
  226   Erylosides B \[[@B63-marinedrugs-13-03154]\]                                                                        *E. lendenfeldi*             

###### 

Steriod structures (**178**--**226**).
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Moderate growth inhibition for a human colon tumor cell line was observed with **180** \[[@B58-marinedrugs-13-03154]\]. Compounds **184** and **186** exhibited activity against three human tumor cell lines including the lung non-small cell line A549, the glioblastoma line U373 and the prostate line PC-3 \[[@B59-marinedrugs-13-03154]\]. Compound **187** showed an IC~50~ of 6.1 and 8.2 μg/mL against the human cancer cell lines HepG2 and HCT, respectively \[[@B24-marinedrugs-13-03154]\].

Compounds **204**--**207** show antibacterial activity against Gram-positive (*Bacillus subtilis*) and Gram-negative bacteria (*Pseudomonas aeruginosa*), at a 1 μg/ml concentration \[[@B64-marinedrugs-13-03154]\]. Compounds **208**--**210** exhibited antitumor activity based on four cancer panels: HepG2, WI 38, VERO, and MCF-7 \[[@B65-marinedrugs-13-03154]\]. Compounds **215**--**220** exhibited cytotoxic effects in the tumor cell lines, HepG2 and MCF-7 with IC~50~ in the range of 20-500 μM. Interestingly, **217** showed the highest affinity to DNA with IC~50~ 30 μg/mL \[[@B66-marinedrugs-13-03154]\]. Compounds **223** and **224** showed antifungal activity against *Candida tropicalis*, with petri dish inhibition at 10 μg/disc \[[@B67-marinedrugs-13-03154]\].

7. Drug Leads
=============

Even though terpenes are the largest group of natural products with over 25,000 structures thus far reported, a small subset of these metabolites have been investigated for biological function and/or activity. Basic biological constituents such as membrane components, hormones, antioxidants and chemical defenses require the isoprenoid building module. Future chemical studies of marine organisms are expected to generate an ensemble of novel terpenes based on progressive knowledge on enzymatic machinery and selective pressures under which such organisms have evolved. The expanding chemo-diversity of marine terpenes is being assisted in part by advanced analytical chemistry methods for structure determination and sophisticated diving techniques for sample collection.

Methods for assaying for *in vitro* biological activity can be more variable in terms of stardardized protocols. The same positive or native chemical controls are not always utilized making direct comparisons of biological activity between different testing laboratories unreliable or at least not reproducible. Moreover, with the paucity of ethnomedical knowledge from marine sources, the basis for selecting the most promising bioassay can be more of an art than a science. The screening for anti-cancer activity in facilities such as the National Cancer Institute (NCI) Chemotherapeutic Agents Repository operated by Fisher BioServices \[[@B71-marinedrugs-13-03154]\] can provide invaluable, cost-free, sensitive screening of hits against multiple-target 60 cancer cell line panels, broadening the opportunity to conduct more comprehensive and mechanistic studies. In the case where a set of metabolites has already been identified possessing a given biological activity, computational, *in silico*, and pharmacophore modeling can guide future design of druggable analogues with better biological activity, without expected toxicity, even if the structural characterization of the biological target(s) is/are not feasible. Such virtual models utilizes steric and electronic descriptors to identify pharmacophoric features such as hydrophobic centroids, aromatic rings, hydrogen bonding acceptors/donors and cation/anion interactions to match optimal supramolecular interactions with a specific biological target that triggers or blocks a response. Functional group properties can also be identified for the rational semi-synthetic design of biologically active marine natural scaffolds. Strategies such as the Topliss scheme designate a series of substituents based on lipophilic, electronic and steric properties to generate multiple analogues with slight controlled chemical property differences that can be used for comprehensive structure-activity studies to obtain superior biological activity relative to the parent natural product. While these techniques and tools are not distinct or exclusive for exploring marine sources and marine-derived natural products, such methods can be effective for enhancing biological activity. For example, sipholenol A is a noteworthy example of developing a marine metabolite using medicinal chemistry approaches to generate biologically active analogue libraries \[[@B49-marinedrugs-13-03154]\]. These natural product examples with exceptional biological potency outcomes (IC~50~ in the low μM range for invasive breast cancer) demonstrate the potential of marine natural products for the discovery of future novel druggable entities useful for the control and management of human diseases.

8. Conclusions
==============

Terpenoids provide a vast array of molecular architectures with the coral community of the Red Sea having added significantly to the structure database over the last thirty years. While marine invertebrates in this ecosystem are still being discovered, interest in both the chemistry and biological activity of Red Sea terpenes has generated many novel structures with promising biological activities.
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